Top Story Today
A $400 Billion Pharma Marriage That Nobody's Cheering For
AstraZeneca and Bristol Myers Squibb are reportedly in talks to combine into a roughly $400 billion pharma colossus, and the market's response was instant and brutal: AstraZeneca shares plunged as much as 7%, while BMS barely budged. Analysts at Jefferies called themselves "perplexed." The core problem is massive oncology overlap (both sell competing checkpoint inhibitors), which would trigger a regulatory nightmare. One portfolio manager said the deal "does not make strategic or financial sense." Talks remain preliminary, but the smart money is already voting no.
Why it matters: A combination of two top-five pharma companies would create the largest biopharma entity in history, fundamentally reshaping global oncology competition. The overwhelmingly negative reaction signals how skeptical investors have become of mega-mergers that promise synergies but historically destroy R&D productivity.
Read more →Deals and M&A
J&J Put $2.58 Billion on a CAR-T Therapy That Doesn't Exist Yet
Johnson & Johnson locked in an exclusive option to acquire Sail Biomedicines for $2.58 billion, paying $785 million upfront for a preclinical in vivo CAR-T platform. The technology uses circular RNA in targeted nanoparticles to reprogram a patient's immune cells with a simple IV drip, no cell harvesting required. The lead program targets autoimmune disease, and Sail's preclinical data showed 50 to 80% T-cell targeting across species.
Read more →Clinical and Regulatory
Sarepta's Gene Therapy Linked to Three Deaths; FDA Slaps Boxed Warning
The FDA is investigating three deaths from acute liver failure tied to Sarepta's Elevidys gene therapy and related products. All victims received drugs using the same AAVrh74 viral vector. The agency added a boxed warning, narrowed the indication to ambulatory patients only, and revoked Sarepta's platform technology designation. Shares fell to around $12.
Read more →FDA Rejects Replimune's Melanoma Virus Therapy for the Third Time
The FDA declined to approve Replimune's oncolytic virus RP1 for advanced melanoma, citing the same single-arm study design flaws it flagged in 2021. Shares crashed roughly 77%. BMO slashed its price target to $1, and JPMorgan removed its target entirely. The company has no approved products, no revenue, and a commercial infrastructure built for a launch that isn't coming.
Read more →AstraZeneca and Ionis Heart Drug Flops, Torching Billions in Market Value
The Phase 3 CARDIO-TTRansform trial for eplontersen in heart disease missed its primary endpoint, erasing billions in combined market cap. The culprit may be trial design: 57% of patients were already on competing stabilizer drugs, burying any incremental benefit. A monotherapy subgroup showed a 29% risk reduction, but analysts say that alone won't support a filing.
Read more →Moderna's mRNA Flu Vaccine Faces Its Biggest Test on Tuesday
The FDA is expected to rule on Moderna's mRNA-1010 on August 5, which would be the first mRNA seasonal flu vaccine ever approved. A unanimous 9-0 advisory committee vote backs approval. The vaccine cut flu illness by 26.6% more than standard shots and reduced medical visits by a third. Approval would validate mRNA technology beyond COVID in the largest vaccine market on the planet.
Read more →Science and Discovery
A Weight-Loss Drug Just Aced an Alcohol Addiction Trial
Altimmune's pemvidutide, a GLP-1/glucagon dual agonist built for obesity, hit every major endpoint in a Phase 2 trial for alcohol use disorder. Patients cut heavy drinking days by 1.45 more days per week than placebo, and a blood biomarker tracking alcohol exposure showed a substantial reduction. The results add hard clinical data to the growing evidence that GLP-1 drugs rewire the brain's reward circuits.
Read more →ARPA-H Bets $160 Million on Turning Custom Gene Editing Into a Playbook
ARPA-H launched a $160 million, five-year program called THRIVE to make bespoke CRISPR therapies repeatable and affordable for rare childhood diseases. Seven teams across institutions like CHOP, the Broad Institute, and Stanford must have patients in clinical trials by year three. The goal: turn heroic one-off gene-editing miracles into standardized platforms that work across thousands of rare conditions.
Read more →